New obesity drug candidate enters early human testing
NCT ID NCT06606106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and how the body handles the drug. Researchers will also measure weight changes and blood sugar levels. The study involves about 300 people and lasts up to 49 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY3537031 (a drug given as an injection under the skin)
What this could lead to
If this early study shows the drug is safe and leads to weight loss, it could point toward a new treatment for obesity.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not weight loss. The drug may not work or could have side effects. Results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Collaborative Neuroscience Research, LLC
Los Alamitos, California, 90720, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
QPS
Springfield, Missouri, 65802, United States